Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK-PPI: Pantoprazole and Psychotropic Medications Interaction
NCT02213887Phase 4Withdrawn
- Sponsor
- University of British Columbia
- Start
- Sep 2014
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of pantoprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by University of British Columbia. Primary endpoint: Change from baseline in steady-state plasma concentrations of psychotropic medication(s) at 9 days. Planned start Sep 2014; status: withdrawn.
02
Drugs
pantoprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT02213887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02213887.